CL2024001157A1 - Formulación farmacéutica que comprende el anticuerpo monoclonal anti-ox40 - Google Patents
Formulación farmacéutica que comprende el anticuerpo monoclonal anti-ox40Info
- Publication number
- CL2024001157A1 CL2024001157A1 CL2024001157A CL2024001157A CL2024001157A1 CL 2024001157 A1 CL2024001157 A1 CL 2024001157A1 CL 2024001157 A CL2024001157 A CL 2024001157A CL 2024001157 A CL2024001157 A CL 2024001157A CL 2024001157 A1 CL2024001157 A1 CL 2024001157A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical formulation
- monoclonal antibody
- disclosed
- subpackaging
- shipping
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021124200 | 2021-10-15 | ||
| CN2022118065 | 2022-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024001157A1 true CL2024001157A1 (es) | 2024-11-15 |
Family
ID=85987310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024001157A CL2024001157A1 (es) | 2021-10-15 | 2024-04-12 | Formulación farmacéutica que comprende el anticuerpo monoclonal anti-ox40 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250282882A1 (https=) |
| EP (1) | EP4415754A4 (https=) |
| JP (1) | JP2024538140A (https=) |
| KR (1) | KR20240109250A (https=) |
| CN (1) | CN118541166A (https=) |
| AU (1) | AU2022367611A1 (https=) |
| CA (1) | CA3235879A1 (https=) |
| CL (1) | CL2024001157A1 (https=) |
| IL (1) | IL312138A (https=) |
| MX (1) | MX2024004619A (https=) |
| PE (1) | PE20241351A1 (https=) |
| TW (1) | TW202323280A (https=) |
| WO (1) | WO2023061424A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20230255A1 (es) * | 2020-04-17 | 2023-02-07 | Hutchison Medipharma Ltd | Anticuerpo anti-ox40 y usos del mismo |
| TW202600166A (zh) * | 2024-03-04 | 2026-01-01 | 新加坡商創響私人有限公司 | 包含ｏｘ４０靶向抗體的藥物組合物及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100014588A (ko) * | 2007-02-27 | 2010-02-10 | 제넨테크, 인크. | 길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도 |
| SG11201607969XA (en) * | 2014-03-31 | 2016-10-28 | Genentech Inc | Anti-ox40 antibodies and methods of use |
| WO2017134292A1 (en) * | 2016-02-04 | 2017-08-10 | Glenmark Pharmaceuticals S.A. | Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis |
| WO2020016417A1 (en) * | 2018-07-19 | 2020-01-23 | Ichnos Sciences S.A. | Liquid antibody formulation |
| WO2020063668A1 (zh) * | 2018-09-25 | 2020-04-02 | 信达生物制药(苏州)有限公司 | 包含抗ox40抗体的制剂、其制备方法及其用途 |
| US20220273796A1 (en) * | 2019-07-19 | 2022-09-01 | Ichnos Sciences SA | Lyophilized antibody formulation |
| WO2021190582A1 (zh) * | 2020-03-25 | 2021-09-30 | 江苏恒瑞医药股份有限公司 | 一种抗ox40抗体药物组合物及其用途 |
-
2022
- 2022-10-11 TW TW111138442A patent/TW202323280A/zh unknown
- 2022-10-13 EP EP22880360.7A patent/EP4415754A4/en active Pending
- 2022-10-13 MX MX2024004619A patent/MX2024004619A/es unknown
- 2022-10-13 PE PE2024000811A patent/PE20241351A1/es unknown
- 2022-10-13 IL IL312138A patent/IL312138A/en unknown
- 2022-10-13 JP JP2024522608A patent/JP2024538140A/ja active Pending
- 2022-10-13 US US18/701,246 patent/US20250282882A1/en active Pending
- 2022-10-13 KR KR1020247016091A patent/KR20240109250A/ko active Pending
- 2022-10-13 WO PCT/CN2022/125017 patent/WO2023061424A1/en not_active Ceased
- 2022-10-13 AU AU2022367611A patent/AU2022367611A1/en active Pending
- 2022-10-13 CA CA3235879A patent/CA3235879A1/en active Pending
- 2022-10-13 CN CN202280069427.XA patent/CN118541166A/zh active Pending
-
2024
- 2024-04-12 CL CL2024001157A patent/CL2024001157A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024004619A (es) | 2024-07-12 |
| TW202323280A (zh) | 2023-06-16 |
| WO2023061424A1 (en) | 2023-04-20 |
| AU2022367611A1 (en) | 2024-05-02 |
| KR20240109250A (ko) | 2024-07-10 |
| US20250282882A1 (en) | 2025-09-11 |
| IL312138A (en) | 2024-06-01 |
| EP4415754A1 (en) | 2024-08-21 |
| JP2024538140A (ja) | 2024-10-18 |
| CA3235879A1 (en) | 2023-04-20 |
| PE20241351A1 (es) | 2024-07-03 |
| CN118541166A (zh) | 2024-08-23 |
| EP4415754A4 (en) | 2025-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024001157A1 (es) | Formulación farmacéutica que comprende el anticuerpo monoclonal anti-ox40 | |
| AR111455A1 (es) | Formulación estable de anticuerpo | |
| CY1122181T1 (el) | Φαρμακοτεχνικη μορφη αντισωματος | |
| AR095396A1 (es) | Formulaciones de anticuerpo | |
| CL2017001115A1 (es) | Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf. | |
| BR112018005349A2 (pt) | preparação farmacêutica de anticorpo anti-pd-1 estável e sua aplicação em medicamentos | |
| BR112016026811A2 (pt) | formulação de anticorpo | |
| EA201792273A1 (ru) | Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела | |
| ECSP21043639A (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| PH12021551916A1 (en) | Therapeutic antibody formulation. | |
| CO2020013571A2 (es) | Formulaciones estables de anticuerpos terapéuticos | |
| CO2022005737A2 (es) | Formulación estable de anticuerpo de integrina | |
| AR120512A1 (es) | Formulaciones que contienen anticuerpos | |
| DOP2024000016A (es) | Proteínas actrii y usos de las mismas | |
| BR112015022946A2 (pt) | forma de dosagem de cápsula de gelatina macia farmacêutica com goma guar modificada | |
| BR112019025591A2 (pt) | Composição farmacêutica compreendendo conjugado de fármaco-anticorpo c-met e uso do mesmo | |
| ZA202212081B (en) | Stable formulation for recombinant anti-pd-1 monoclonal antibody | |
| CL2024003444A1 (es) | Formulación farmacéutica líquida estable que comprende un anticuerpo biespecífico anti-cd20/cd3 humano. | |
| AR117607A1 (es) | Formulaciones de anticuerpo líquidas de alta concentración | |
| CO2020013545A2 (es) | Formulación estable de anticuerpos | |
| BR112022001775A2 (pt) | Formulação compreendendo o anticorpo biespecífico anti-pd-1/her2, método para preparo e uso do mesmo | |
| PE20251269A1 (es) | Nuevo cocristal de enavogliflozina | |
| MX2024004656A (es) | Formulaciones acuosas de un anticuerpo anti-cd22 y usos de las mismas. | |
| AR102572A1 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf | |
| CL2020000356A1 (es) | Composiciones farmacéuticas. |